Diversifying across a portfolio of vaccine types and funding mechanisms is essential because any vaccine can fail at any stage—exemplified by the AstraZeneca/Oxford trial being paused over a negative effect despite 2 billion pre-ordered doses—so policy should take many 'shots on goal' since the winning candidate is unknown.
causalpending
Speaker
Alex TabarrokEvidence Quote
“the astrazeneca vaccine for example this was early out of the gate... last week the trial one of the clinical trials was shut down because they had a negative effect”
Created: 6/13/2026, 7:01:25 PM
Your notes
Loading notes...